A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen
1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butaned...
Gespeichert in:
Veröffentlicht in: | Journal of applied toxicology 2006-01, Vol.26 (1), p.72-80 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 80 |
---|---|
container_issue | 1 |
container_start_page | 72 |
container_title | Journal of applied toxicology |
container_volume | 26 |
creator | Irwin, Richard D. |
description | 1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/jat.1110 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19712893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14772338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</originalsourceid><addsrcrecordid>eNqF0VtPFDEUB_DGaGQBEz-B6YuGBwd7mZm2jxvCVRBNUHlrzrQdLM5O17YL8u3pZifwZHzq7Zdz2n8RekvJPiWEfbqFvE8pJS_QjBKlKspa_hLNCGtJVXNxvYW2U7olpJwx-Rpt0ZYq3vB6hn7McXR33t3j0OMysW40Dg8OrB9vcA44_3J4GZ31JvswliVkTD_WVbfKMJbtMGCf8BgyBmwgGj-GGzfuolc9DMm9mcYd9P3o8OrgpDq_PD49mJ9XppacVKIxnRK17BUAsURYDr0hEmwHZatjwNuO9MpJUytrXNNQ2TZGUiZYea2VfAd92NRdxvBn5VLWC5-MG4Zyt7BKmipBmVT8_7AWgnG-rri3gSaGlKLr9TL6BcQHTYleh61L2HoddqHvppqrbuHsM5zSLeD9BCAZGPoIo_Hp2YmasfIpxVUbd-8H9_DPhvpsfjU1nrxP2f198hB_61Zw0eifX47157OTr0cX198054_piqNa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14772338</pqid></control><display><type>article</type><title>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Irwin, Richard D.</creator><creatorcontrib>Irwin, Richard D.</creatorcontrib><description>1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0260-437X</identifier><identifier>EISSN: 1099-1263</identifier><identifier>DOI: 10.1002/jat.1110</identifier><identifier>PMID: 16193534</identifier><identifier>CODEN: JJATDK</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>1.4-butanediol ; 4-Butyrolactone - toxicity ; Animals ; Biological and medical sciences ; Biotransformation ; Butylene Glycols - pharmacokinetics ; Butylene Glycols - toxicity ; Carcinogenesis, carcinogens and anticarcinogens ; carcinogenicity ; Carcinogenicity Tests ; Chemical agents ; Humans ; Hydroxybutyrates - metabolism ; Hydroxybutyrates - toxicity ; Medical sciences ; metabolism ; Solvents - toxicity ; Toxicology ; Tumors ; γ-butyrolactone ; γ-hydroxybutyric acid</subject><ispartof>Journal of applied toxicology, 2006-01, Vol.26 (1), p.72-80</ispartof><rights>Copyright © 2005 John Wiley & Sons, Ltd.</rights><rights>2006 INIST-CNRS</rights><rights>2005 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</citedby><cites>FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjat.1110$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjat.1110$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17422000$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16193534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Irwin, Richard D.</creatorcontrib><title>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</title><title>Journal of applied toxicology</title><addtitle>J. Appl. Toxicol</addtitle><description>1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley & Sons, Ltd.</description><subject>1.4-butanediol</subject><subject>4-Butyrolactone - toxicity</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biotransformation</subject><subject>Butylene Glycols - pharmacokinetics</subject><subject>Butylene Glycols - toxicity</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>carcinogenicity</subject><subject>Carcinogenicity Tests</subject><subject>Chemical agents</subject><subject>Humans</subject><subject>Hydroxybutyrates - metabolism</subject><subject>Hydroxybutyrates - toxicity</subject><subject>Medical sciences</subject><subject>metabolism</subject><subject>Solvents - toxicity</subject><subject>Toxicology</subject><subject>Tumors</subject><subject>γ-butyrolactone</subject><subject>γ-hydroxybutyric acid</subject><issn>0260-437X</issn><issn>1099-1263</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0VtPFDEUB_DGaGQBEz-B6YuGBwd7mZm2jxvCVRBNUHlrzrQdLM5O17YL8u3pZifwZHzq7Zdz2n8RekvJPiWEfbqFvE8pJS_QjBKlKspa_hLNCGtJVXNxvYW2U7olpJwx-Rpt0ZYq3vB6hn7McXR33t3j0OMysW40Dg8OrB9vcA44_3J4GZ31JvswliVkTD_WVbfKMJbtMGCf8BgyBmwgGj-GGzfuolc9DMm9mcYd9P3o8OrgpDq_PD49mJ9XppacVKIxnRK17BUAsURYDr0hEmwHZatjwNuO9MpJUytrXNNQ2TZGUiZYea2VfAd92NRdxvBn5VLWC5-MG4Zyt7BKmipBmVT8_7AWgnG-rri3gSaGlKLr9TL6BcQHTYleh61L2HoddqHvppqrbuHsM5zSLeD9BCAZGPoIo_Hp2YmasfIpxVUbd-8H9_DPhvpsfjU1nrxP2f198hB_61Zw0eifX47157OTr0cX198054_piqNa</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>Irwin, Richard D.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>C1K</scope><scope>SOI</scope><scope>7U7</scope></search><sort><creationdate>200601</creationdate><title>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</title><author>Irwin, Richard D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>1.4-butanediol</topic><topic>4-Butyrolactone - toxicity</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biotransformation</topic><topic>Butylene Glycols - pharmacokinetics</topic><topic>Butylene Glycols - toxicity</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>carcinogenicity</topic><topic>Carcinogenicity Tests</topic><topic>Chemical agents</topic><topic>Humans</topic><topic>Hydroxybutyrates - metabolism</topic><topic>Hydroxybutyrates - toxicity</topic><topic>Medical sciences</topic><topic>metabolism</topic><topic>Solvents - toxicity</topic><topic>Toxicology</topic><topic>Tumors</topic><topic>γ-butyrolactone</topic><topic>γ-hydroxybutyric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Irwin, Richard D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Environment Abstracts</collection><collection>Toxicology Abstracts</collection><jtitle>Journal of applied toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Irwin, Richard D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</atitle><jtitle>Journal of applied toxicology</jtitle><addtitle>J. Appl. Toxicol</addtitle><date>2006-01</date><risdate>2006</risdate><volume>26</volume><issue>1</issue><spage>72</spage><epage>80</epage><pages>72-80</pages><issn>0260-437X</issn><eissn>1099-1263</eissn><coden>JJATDK</coden><abstract>1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>16193534</pmid><doi>10.1002/jat.1110</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0260-437X |
ispartof | Journal of applied toxicology, 2006-01, Vol.26 (1), p.72-80 |
issn | 0260-437X 1099-1263 |
language | eng |
recordid | cdi_proquest_miscellaneous_19712893 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | 1.4-butanediol 4-Butyrolactone - toxicity Animals Biological and medical sciences Biotransformation Butylene Glycols - pharmacokinetics Butylene Glycols - toxicity Carcinogenesis, carcinogens and anticarcinogens carcinogenicity Carcinogenicity Tests Chemical agents Humans Hydroxybutyrates - metabolism Hydroxybutyrates - toxicity Medical sciences metabolism Solvents - toxicity Toxicology Tumors γ-butyrolactone γ-hydroxybutyric acid |
title | A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T18%3A07%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20of%20evidence%20leading%20to%20the%20prediction%20that%201,4-butanediol%20is%20not%20a%20carcinogen&rft.jtitle=Journal%20of%20applied%20toxicology&rft.au=Irwin,%20Richard%20D.&rft.date=2006-01&rft.volume=26&rft.issue=1&rft.spage=72&rft.epage=80&rft.pages=72-80&rft.issn=0260-437X&rft.eissn=1099-1263&rft.coden=JJATDK&rft_id=info:doi/10.1002/jat.1110&rft_dat=%3Cproquest_cross%3E14772338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14772338&rft_id=info:pmid/16193534&rfr_iscdi=true |